Abstracts tagged "Clinical practice"

Abstract Number: 117 • 2015 ACR/ARHP Annual Meeting
Same Day Rheumatology Access Clinic in an Academic Health Care Center
Muhammad Ijaz^1,2, Alireza Meysami¹, Amita Bishnoi¹ and Bernard Rubin³, ¹Rheumatology, Henry Ford Hospital, Detroit, MI, ²Rheumatology, Wayne State University/Detroit Medical Center, Detroit, MI, ³Rheumatology, Henry Ford Health System, Detroit, MI
Background/Purpose: Open access clinics have been studied extensively in the primary care setting 1, but there is limited data regarding rheumatology open access clinics. To…
Abstract Number: 2418 • 2015 ACR/ARHP Annual Meeting
Pediatric Enthesitis-Related Arthritis: Variation in Disease Characteristics and Treatments Among 5 Large Centers
Sabrina Gmuca¹, Timothy Brandon², Rui Xiao³, Ilaria Pagnini⁴, Tracey B. Wright⁵, Timothy Beukelman⁶, Esi Morgan-DeWitt⁷ and Pamela F. Weiss⁸, ¹Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, ³Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁴Department of Paediatrics, University of Florence and Anna Meyer Children's Hospital, Florence, Italy, Florence, Italy, ⁵Pediatrics/Rheumatology, Univ of TX Southwestern, Dallas, TX, ⁶Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Pediatric rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: We aimed to compare the clinical features and treatments of children with Enthesitis-related arthritis (ERA) from 5 pediatric rheumatology centers in order to determine…
Abstract Number: 132 • 2015 ACR/ARHP Annual Meeting
Delivering a One-Stop, Integrated, Patient-Centred Service for Patients with Rheumatic Diseases. the Finnish Approach
Elena Nikiphorou¹, Paula Väre¹, Kirsi Paalanen¹, Jelena Borodina¹, Arto Kokko², Pekka Hannonen¹ and Tuulikki Sokka-Isler³, ¹Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Jyvaskyla Central Hospital, Jyväskylä, Finland, ³Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Rheumatology is mainly an outpatient specialty. Prompt diagnosis & treatment to prevent long-term disability in an integrated, multi-disciplinary approach to care are crucial. In reality though,…
Abstract Number: 2489 • 2015 ACR/ARHP Annual Meeting
Effects of Two Interventions on Rheumatologists Adherence to Optimal Care Recommendations in Rheumatoid Arthritis: A Combined before/after and Randomized Controlled Trial
Nienke Lesuis¹, Ronald van Vollenhoven², Marlies Hulscher³ and Alfons den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²ClinTRID, Department of Medicine, Karolinska Institute, Stockholm, Sweden, ³IQ Healthcare, Radboud University Medical Centre, Nijmegen, Netherlands
Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend using tight control strategies.1 Despite evidence for the benefits of this strategy, physician adherence is suboptimal.2,3…
Abstract Number: 185 • 2015 ACR/ARHP Annual Meeting
Success Rate and Utility of Ultrasound Guided Synovial Biopsies in Clinical Practice
Aurélie Najm, Benoît Le Goff and Yves Maugars, Rheumatology, Rheumatology, Nantes, France
Background/Purpose: Histological and bacteriological analysis of synovial tissue (ST) can be useful in the diagnosis of arthritis of undetermined origin. Ultrasound can assist this biopsy…
Abstract Number: 2612 • 2015 ACR/ARHP Annual Meeting
Impact of a Multibiomarker Disease Activity Score in Patients with Rheumatoid Arthritis Treated in a Real World Setting
Sergio Schwartzman¹, Keith Knapp², Gary Craig³, Karen Ferguson⁴ and Howard Kenney⁵, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Arthritis Northwest, Spokane, WA, ³Discus Analytics, Inc., Spokane, WA, ⁴Arthritis Northwest PLLC., Spokane, WA, ⁵Rheumatology, Arthritis Northwest, Spokane, WA
Background/Purpose: A number of composite outcome measures have been validated to quantify disease activity in Rheumatoid Arthritis (RA). Few studies have been published on the…
Abstract Number: 256 • 2015 ACR/ARHP Annual Meeting
The Predominant Attack Type and Associated Clinical-Laboratory Conditions in Patients with Familial Mediterranean Fever
Mustafa Cakar¹, Muharrem Akhan², Muhammet Cinar¹ and Sedat Yılmaz¹, ¹Rheumatology, Gulhane Medical Faculty, Ankara, Turkey, ²Internal Medicine, Gulhane Medical Faculty, Ankara, Turkey
Background/Purpose: Familial Mediterranean Fever (FMF) is an autoinflammatory disease characterized by recurrent attacks of fever and serositis. Abdominal pain is the most frequent symptom of…
Abstract Number: 2666 • 2015 ACR/ARHP Annual Meeting
Trajectories of EQ-5D in RA Patients Treated with Biologics Using the IORRA Cohort
Daisuke Hoshi, Eiichi Tanaka, Eisuke Inoue, Yoko Shimizu, Naoki Sugimoto, Kumi Shidara, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Patient-reported outcomes are recognized as important for evaluating the disease status of rheumatoid arthritis (RA). The EuroQol 5-dimensional descriptive system (EQ-5D) has been used…
Abstract Number: 433 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA) Biologic Switching and Cycling in a Large US Managed Care Population
Machaon Bonafede¹, Jeffrey R. Curtis², Donna McMorrow¹, Chieh-I Chen³ and George J. Joseph⁴, ¹Truven Health Analytics, Cambridge, MA, ²Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Global Health Economics & Outcomes Research (HEOR), Sanofi, Bridgewater, NJ
Background/Purpose: A majority of RA patients who switch from a tumor necrosis factor inhibitor (TNFi) to another biologic disease-modifying anti-rheumatic drug (DMARD) are TNFi cyclers…
Abstract Number: 2729 • 2015 ACR/ARHP Annual Meeting
Clinical and Radiographic Outcome of Iguratimod for Rheumatoid Arthritis
Tsuneo Kondo, Akiko Shibata, Ryota Sakai, Jun Kikuchi, Kentaro Chino, Ayumi Okuyama, Hirofumi Takei and Koichi Amano, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Background/Purpose: Iguratimod is a new small-molecular drug for rheumatoid arthritis (RA), which was approved on June, 2012 in Japan. The agent inhibits the production of…
Abstract Number: 448 • 2015 ACR/ARHP Annual Meeting
A Majority of Early Rheumatoid Arthritis (ERA) Patients Reach Remission By 6 Months in Usual Rheumatology Care
Tuomas Rannio¹, Juha Asikainen², Pekka Hannonen³, Timo Yli-Kerttula⁴, Päivi Ekman⁵, Laura Pirilä⁶, Markku Mali⁷, Laura Kuusela⁷, Maija Puurtinen-Vilkki⁷, Saara Kortelainen⁸, Johanna Paltta⁷, Kirsi Taimen⁷, Heidi Mäkinen⁹, Pia Isomäki⁹, Terhi Uotila⁹, Markku J. Kauppi¹⁰, Kari Laiho¹¹, Satu Nyrhinen¹¹, Tuulikki Sokka-Isler¹ and FIN-ERA study group, ¹Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Jyväskylä Central Hospital, Jyväskylä, Finland, ³Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁴Sairaalantie 3, Central Hospital of Satakunta, Pori, Finland, ⁵Central Hospital of Satakunta, Pori, Finland, ⁶Tyks, P.O. Box 52, Turku University Central Hospital, Turku, Finland, ⁷Turku University Central Hospital, Turku, Finland, ⁸Alvar Aallontie 275, Turku University Central Hospital, Turku, Finland, ⁹Tampere University Hospital, Tampere, Finland, ¹⁰Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ¹¹Päijät-Häme Central Hospital, Lahti, Finland
Background/Purpose: Finnish national combination treatment trials have demonstrated excellent outcomes in patients with ERA including 90% of patients reaching DAS28 remission at 6 months. Whether…
Abstract Number: 3181 • 2015 ACR/ARHP Annual Meeting
How Common Is Inactive Disease in a Prospective Cohort of Patients with Juvenile Idiopathic Arthritis? the Importance of Definition
Stephanie Shoop¹, Suzanne M. Verstappen², Eileen Baildam³, Alice Chieng⁴, Joyce Davidson^5,6, Helen Foster⁷, Yiannis Ioannou⁸, Flora McErlane⁷, Lucy R Wedderburn⁹, Wendy Thomson¹⁰ and Kimme L. Hyrich¹⁰, ¹ARC Epidemiology, Stopford Building, ARC Epidemiology Unit, The University of Manchester, M13 9PT, United Kingdom, ²ARC Epidemiology, Stopford Building, ARC Epidemiology Unit, the University of Manchester, Manchester, United Kingdom, ³Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁴Royal Manchester Children's Hospital, Manchester, United Kingdom, ⁵The Royal Hospital for Sick Children, Glasgow, Glasgow, United Kingdom, ⁶The Royal Hospital for Sick Children, Edinburgh, Edinburgh, United Kingdom, ⁷Royal Victoria Hospital, Newcastle, United Kingdom, ⁸Rayne Institute, University College London, London, UK, London, United Kingdom, ⁹Great Ormond Street Hospital NHS Foundation Trust, Paediatric Rheumatology, London, United Kingdom, ¹⁰arc Epidemiology Unit, Manchester, United Kingdom
Background/Purpose: Patients with JIA are at risk of disability, pain and joint damage in the longer-term. Treating toward clinically inactive disease (ID) has the potential…
Abstract Number: 504 • 2015 ACR/ARHP Annual Meeting
Influence of CDAI Measurement on the Decision of Community Rheumatologists to Initiate or Change Biologic Treatment
Alan K. Matsumoto¹, Herbert S. B. Baraf², Janna Radtchenko³, Jason Drenning⁴ and Bruce Feinberg⁵, ¹Rheumatology, Arthritis & Rheumatism Assoc, Wheaton, MD, ²The Center for Rheumatology and Bone Research, Wheaton, MD, ³Health Care Analytics, Cardinal Health, Dallas, TX, ⁴Healthcare Analytics, Cardinal health, Dallas, TX, ⁵Cardinal Health, Dublin, OH
Background/Purpose: Periodic measurement of disease activity using validated tools such as the Clinical Disease Activity Index (CDAI) is considered an important aspect of care for…
Abstract Number: 3185 • 2015 ACR/ARHP Annual Meeting
A Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach in the Clinical Care of Rheumatoid Arthritis Patients in the United States
Leslie Harrold^1,2, George W. Reed^1,2, J. Timothy Harrington³, Christine J. Barr¹, Katherine C. Saunders¹, Allan Gibofsky⁴, Eric M. Ruderman⁵, Tmirah Haselkorn⁶, Jeffrey D. Greenberg^1,7, Ani John⁶ and Joel M. Kremer⁸, ¹Corrona, LLC, Southborough, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Joiner Associates, LLC, Madison, WI, ⁴Hospital for Special Surgery, New York, NY, ⁵Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Genentech, Inc, South San Francisco, CA, ⁷NYU School of Medicine, New York, NY, ⁸Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: We report the results of a cluster-randomized behavioral intervention trial designed to assess the impact of implementing a treat-to-target (T2T) approach vs usual care…
Abstract Number: 506 • 2015 ACR/ARHP Annual Meeting
Evaluation of Persistence and Outcomes in Patients Treated with TNF and Non-TNF Biologics Following Treatment Clinical Pathway in Rheumatoid Arthritis
Alan K. Matsumoto¹, Herbert S. B. Baraf², Janna Radtchenko³, Jason Drenning⁴ and Bruce Feinberg⁵, ¹Rheumatology, Arthritis & Rheumatism Assoc, Wheaton, MD, ²The Center for Rheumatology and Bone Research, Wheaton, MD, ³Health Care Analytics, Cardinal Health, Dallas, TX, ⁴Healthcare Analytics, Cardinal health, Dallas, TX, ⁵Cardinal Health, Dublin, OH
Background/Purpose: Use of biologic agents for the treatment of rheumatoid arthritis continues to grow rapidly, with the cost of these agents putting a significant strain…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].